PE20191320A1 - Constructos de vacuna y sus usos contra infecciones causadas por staphylococcus - Google Patents

Constructos de vacuna y sus usos contra infecciones causadas por staphylococcus

Info

Publication number
PE20191320A1
PE20191320A1 PE2019000844A PE2019000844A PE20191320A1 PE 20191320 A1 PE20191320 A1 PE 20191320A1 PE 2019000844 A PE2019000844 A PE 2019000844A PE 2019000844 A PE2019000844 A PE 2019000844A PE 20191320 A1 PE20191320 A1 PE 20191320A1
Authority
PE
Peru
Prior art keywords
seq
polypeptide
amino acid
construct
absent
Prior art date
Application number
PE2019000844A
Other languages
English (en)
Spanish (es)
Inventor
François Malouin
Celine Ster
Julie Côte-Gravel
Eric Brouillette
Original Assignee
Socpra Sciences Et Genie Sec
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Socpra Sciences Et Genie Sec filed Critical Socpra Sciences Et Genie Sec
Publication of PE20191320A1 publication Critical patent/PE20191320A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/085—Staphylococcus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/305—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Micrococcaceae (F)
    • C07K14/31—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Micrococcaceae (F) from Staphylococcus (G)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/74—Vectors or expression systems specially adapted for prokaryotic hosts other than E. coli, e.g. Lactobacillus, Micromonospora
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
    • A61K2039/522—Bacterial cells; Fungal cells; Protozoal cells avirulent or attenuated
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • A61K2039/552—Veterinary vaccine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
    • C07K2319/21—Fusion polypeptide containing a tag with affinity for a non-protein ligand containing a His-tag

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • General Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Microbiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Communicable Diseases (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Oncology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
PE2019000844A 2016-10-21 2017-10-20 Constructos de vacuna y sus usos contra infecciones causadas por staphylococcus PE20191320A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201662411120P 2016-10-21 2016-10-21

Publications (1)

Publication Number Publication Date
PE20191320A1 true PE20191320A1 (es) 2019-09-24

Family

ID=62018642

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2019000844A PE20191320A1 (es) 2016-10-21 2017-10-20 Constructos de vacuna y sus usos contra infecciones causadas por staphylococcus

Country Status (24)

Country Link
US (2) US11324815B2 (OSRAM)
EP (1) EP3529260A4 (OSRAM)
JP (2) JP7181208B2 (OSRAM)
KR (1) KR20190082229A (OSRAM)
CN (1) CN109843910A (OSRAM)
AR (1) AR109847A1 (OSRAM)
AU (2) AU2017346974B2 (OSRAM)
BR (1) BR112019007796A2 (OSRAM)
CA (1) CA3037070A1 (OSRAM)
CL (1) CL2019001048A1 (OSRAM)
CO (1) CO2019005169A2 (OSRAM)
CR (1) CR20190249A (OSRAM)
DO (1) DOP2019000102A (OSRAM)
IL (1) IL265869A (OSRAM)
MX (2) MX2019004539A (OSRAM)
MY (1) MY195369A (OSRAM)
NZ (1) NZ751880A (OSRAM)
PE (1) PE20191320A1 (OSRAM)
PH (1) PH12019500843A1 (OSRAM)
RU (2) RU2022100889A (OSRAM)
SG (2) SG10201912431XA (OSRAM)
TW (1) TW201819402A (OSRAM)
UY (1) UY37448A (OSRAM)
WO (1) WO2018072031A1 (OSRAM)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113777317A (zh) * 2020-06-09 2021-12-10 首都医科大学附属北京世纪坛医院 尿液主穹隆蛋白及其多肽片段在烧伤中的应用
US20220185852A1 (en) * 2020-12-11 2022-06-16 Bayer Animal Health Gmbh Methods and compositions for improved production of an antigen for use in an s. aureus vaccine
WO2026014994A1 (ko) * 2024-07-12 2026-01-15 주식회사 더윤헬스텍 젖소 유방염 유래 대장균 또는 황색 포도알균 변이주 및 이를 포함하는 백신 조성물
US12161970B1 (en) 2024-08-09 2024-12-10 Jiaxing Research Institute, Zhejiang University CO2 desorption system suitable for limited space in complex sailing region and flexible control method

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1288774C (en) 1985-01-07 1991-09-10 Deborah A. Eppstein 1,2-dialkoxy-w-trialkylammonium cationic surfactants
US6228844B1 (en) 1991-11-12 2001-05-08 Vical Incorporated Stimulating vascular growth by administration of DNA sequences encoding VEGF
US7060458B1 (en) 1997-08-14 2006-06-13 Wyeth Nucleic acid and amino acid sequences relating to Staphylococcus epidermidis for diagnostics and therapeutics
US6380370B1 (en) * 1997-08-14 2002-04-30 Genome Therapeutics Corporation Nucleic acid and amino acid sequences relating to Staphylococcus epidermidis for diagnostics and therapeutics
US6833134B2 (en) 2000-06-12 2004-12-21 University Of Saskacthewan Immunization of dairy cattle with GapC protein against Streptococcus infection
GB0107661D0 (en) 2001-03-27 2001-05-16 Chiron Spa Staphylococcus aureus
MXPA05005045A (es) 2002-11-12 2005-07-01 Brigham & Womens Hospital Vacuna de polisacarido para infecciones estafilococicas.
CN1569893A (zh) 2003-07-21 2005-01-26 中国人民解放军军事医学科学院基础医学研究所 金葡菌毒力因子调控蛋白的抗原表位及其模拟表位和用途
RU2419628C2 (ru) 2004-09-22 2011-05-27 ГлаксоСмитКлайн Байолоджикалз с.а. Иммуногенная композиция для применения в вакцинации против стафилококков
BRPI0516974A (pt) * 2004-10-21 2008-09-30 Wyeth Corp composição imunogênica compreendendo um polipeptìdeo; um método para induzir uma resposta imune contra staphylococcus epidermidis; um método para induzir uma resposta imune contra staphylococcus aureus; um método para a detecção e/ou identificação de staphylococcus epidermidis; um método para a detecção e/ou identificação de anticorpos para staphylococcus epidermidis
KR100729954B1 (ko) 2004-12-01 2007-06-20 주식회사 엘지생명과학 Sec1 변이 단백질의 제형 및 그것의 제형화 방법
CA2667788A1 (en) 2006-10-30 2008-12-18 The University Of Western Ontario Staphylococcus aureus specific anti-infectives
EP2411046B1 (en) 2009-03-23 2017-12-06 Epitopix, LLC Polypeptides and immunizing compositions containing gram positive polypeptides and methods of use
NZ612315A (en) 2009-04-14 2014-10-31 Novartis Ag Compositions for immunising against staphylococcus aureus
CA2792956C (en) * 2010-03-17 2021-11-16 Socpra - Sciences Et Genie, S.E.C. Bacterial vaccine components from staphylococcus aureus and uses thereof
BR112013032774B1 (pt) 2011-06-19 2020-05-05 Univ New York composições compreendendo proteína luke isolada ou polipeptídeo da mesma, uma proteína lukd isolada ou polipeptídeo da mesma ou sua combinação, bem como seu uso

Also Published As

Publication number Publication date
JP2019531100A (ja) 2019-10-31
CO2019005169A2 (es) 2019-08-09
RU2019115303A3 (OSRAM) 2021-03-02
MY195369A (en) 2023-01-16
AU2017346974A1 (en) 2019-03-14
KR20190082229A (ko) 2019-07-09
AU2017346974B2 (en) 2022-03-31
JP2023025066A (ja) 2023-02-21
EP3529260A1 (en) 2019-08-28
MX2023001219A (es) 2023-03-03
RU2766354C2 (ru) 2022-03-15
AU2022204585A1 (en) 2022-07-21
TW201819402A (zh) 2018-06-01
JP7181208B2 (ja) 2022-11-30
AR109847A1 (es) 2019-01-30
PH12019500843A1 (en) 2019-12-02
US20220288183A1 (en) 2022-09-15
CR20190249A (es) 2019-10-16
WO2018072031A1 (en) 2018-04-26
US11324815B2 (en) 2022-05-10
UY37448A (es) 2018-03-23
CA3037070A1 (en) 2018-04-26
EP3529260A4 (en) 2020-12-16
BR112019007796A2 (pt) 2019-09-03
RU2019115303A (ru) 2020-11-23
DOP2019000102A (es) 2019-07-15
CL2019001048A1 (es) 2019-08-30
IL265869A (en) 2019-06-30
SG11201901483QA (en) 2019-03-28
CN109843910A (zh) 2019-06-04
SG10201912431XA (en) 2020-02-27
NZ751880A (en) 2023-04-28
US20190216913A1 (en) 2019-07-18
MX2019004539A (es) 2019-06-12
RU2022100889A (ru) 2022-04-06

Similar Documents

Publication Publication Date Title
CL2018002825A1 (es) Vacuna contra vrs
CY1123189T1 (el) Αντιμικροβiακο πεπτιδιο
CY1118331T1 (el) Χιμαιρικα πολυπεπτιδια και η χρηση τους στην εκριζωση φορειας βακτηριων
ES2722799T3 (es) Vacunas contra el cáncer de cerebro basadas en el péptido alfa 2 del receptor de interleuquina-13
PE20090483A1 (es) Vectores para la expresion multiple de genes
GB201206559D0 (en) Polypeptide
CU24570B1 (es) Proteínas de bacillus thuringiensis quiméricas insecticidas tóxicas o inhibidoras de plagas de lepidópteros
PE20140986A1 (es) Proteinas de fusion y vacunas de combinacion que comprenden proteina e y pilina a de haemophilus influenzae
JP2014000092A5 (OSRAM)
ECSP10010637A (es) Anticuerpos anti-factor d humanizados y sus usos
MX2019005269A (es) Formulaciones estables de dominios variables sencillos de inmunoglobulina y usos de las mismas.
CO2019005169A2 (es) Constructos de vacuna y sus usos contra infecciones causadas por staphylococcus
CO6731074A2 (es) Composición vacunal para el control de las infestaciones por ectoparásitos
UA116431C2 (uk) Композиція для попередження інфекції mycoplasma spp.
MX2016006277A (es) Secuencia de endolisina kz144 modificada.
CU20210061A7 (es) Composición vacunal que comprende el dominio alfa 3 de mica/b para el tratamiento del cáncer
AR102963A1 (es) Composiciones y métodos para controlar las plagas en plantas
AR100310A1 (es) Moléculas para transporte de antígeno modular mejoradas y sus usos
MX2009007261A (es) Vacuna de peptido foxp3.
MX2018001200A (es) Nuevos microorganismos y su uso en la agricultura.
MX348934B (es) Secuencias de aminoacidos para el control de patogenos.
BR102013026625A8 (pt) vacina de peptídeos recombinantes para o controle de carrapatos e sequências de nucleotídeos codificadoras dos peptídeos recombinantes
CO6690750A2 (es) Compuestos de ditiínatetra (tio) carboximidas y procedimientos para la preparación de estos compuestos
BR112022010228A2 (pt) Vacinas de parasita de leishmania viva atenuada com características de segurança aumentadas
PL405911A1 (pl) Białko o aktywności hydrolitycznej wobec polisacharydowych otoczek bakteryjnych, polinukleotyd kodujący to białko, biologicznie czynny wektor, kompozycja zawierająca białko i jego zastosowanie